Here, 185 patients with metastatic IDH1-mutant CCA refractory to up to two previous lines of gemcitabine-based or fluorouracil-based chemotherapy were randomized to receive the oral IDH1 inhibitor ivosidenib or placebo. The gene discussed is IDH1; the disease is cholangiocarcinoma.